News & Media

Nov 02, 2021

Arthrosi Presents AR882 Posters at ACR 2021

Arthrosi Therapeutics, Inc., a clinical-stage biotech company announced results from its renal impairment studies and human AME study.

Read More
Oct 12, 2021

Arthrosi Appoints Robert Thomas Keenan MD, MPH, MBA as Chief Medical Officer

Dr. Keenan has spent nearly 20 years in the field of rheumatology, bringing his vast expertise to the team as they reach Phase2b in the clinical development of the next generation molecule for the treatment of gout.

Read More
Aug 17, 2021

Arthrosi Establishes Joint Venture in China to Accelerate Development of Innovative Drug Portfolio

Arthrosi Therapeutics, Inc. today announced a joint venture in Guangzhou China with Ruiao Biopharmaceutical Technology Co., Ltd. ("a subsidiary of  ApicHope  Phamaceutical") to form Guangzhou Ruianbo Pharmaceutical Technology Co., Ltd.

Read More
Jun 01, 2021

Arthrosi Therapeutics, Inc. Announces Impressive Phase 2a Study Results

With AR882 showing strong efficacy and safety profile in Phase 2a study, Arthrosi is accelerating the development and looking to complete the Phase 2 studies by the middle of 2022.

Read More
May 10, 2021

Arthrosi’s New Molecule AR882 for Gout Shows Blockbuster-Potential

Our mission is to eliminate the pain of gout with a new era of gout treatment that provides a true solution. 

Read More
Apr 20, 2021

Arthrosi Expands Disease Expertise with New Board of Director Appointment

Arthrosi Therapeutics, Inc. today announced the appointment of James Mackay, PhD, to its board of directors.   

Read More